Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - zinc oxide - cutaneous cream - 320mg/1gram

Європейський Союз - англійська - EMA (European Medicines Agency)

ipsen pharma - mecasermin - laron syndrome - pituitary and hypothalamic hormones and analogues - for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary igfd).severe primary igfd is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (igf-1) levels below the 2.5th percentile for age and gender and;growth hormone (gh) sufficiency;exclusion of secondary forms of igf-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.severe primary igfd includes patients with mutations in the gh receptor (ghr), post-ghr signalling pathway, and igf-1 gene defects; they are not gh deficient, and therefore, they cannot be expected to respond adequately to exogenous gh treatment. it is recommended to confirm the diagnosis by conducting an igf-1 generation test.

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

pharma-z ltd - zinc sulfate - oral capsule - 220mg

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - zinc chloride, quantity: 5.3 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid - indications as at 01 jan 1991 : zinc chloride injection is intended for use as an additive to compatible intravenous fluids or total parenteral nutrition solutions. it is indicated for the prevention and treatment of zinc deficiency, which may be characterised by growth deterioration, skin lesions, alopecia, impaired reproductive development and function, and delayed or inhibited wound healing. indications as at 01 jan 1991 : zinc chloride injection is intended for use as an additive to compatible intravenous fluids or total parenteral nutrition solutions. it is indicated for the prevention and treatment of zinc deficiency, which may be characterised by growth deterioration, skin lesions, alopecia, impaired reproductive development and function, and delayed or inhibited wound healing.

Сінгапур - англійська - HSA (Health Sciences Authority)

aguettant asia pacific pte. ltd. - zinc gluconate eqv elemental zinc - infusion, solution concentrate - zinc gluconate eqv elemental zinc 1mg/ml

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

care pharmaceuticals pty ltd - zinc oxide -

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

j m loveridge ltd - zinc oxide - cutaneous ointment - 150mg/1gram

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - zinc oxide - cutaneous ointment - 150mg/1gram

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - zinc chloride, quantity: 5.3 mg/ml - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - zinc chloride injection is intended for use as an additive to compatible intravenous fluids or total parenteral nutrition solutions. it is indicated for the prevention and treatment of zinc deficiency, which may be characterised by growth deterioration, skin lesions, alopecia, impaired reproductive development and function, and delayed or inhibited wound healing.

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

j m loveridge ltd - zinc oxide - cutaneous cream - 320mg/1gram